Table 2. Inhibitory Activities^a (μM) of the Investigated Compounds 1–14 against Aβ Aggregation, ChEs, and MAOs.

	IC50 (μM) or (% inhibition)b
compd	Aβ40 aggr	eeAChE	esBChE	hMAO A	hMAO B
1	(63 ± 3)c	(39 ± 1)	(8 ± 3)	(<5)	(22 ± 4)
2	3.2 ± 0.8	9.2 ± 0.6	(26 ± 3)	3.6 ± 0.3	0.0077 ± 0.0013
3	4.4 ± 0.3	7.9 ± 0.8	(24 ± 1)	(41 ± 3)	0.031 ± 0.001
4	8.2 ± 0.3	3.5 ± 0.3	(35 ± 3)	3.0 ± 0.2	0.054 ± 0.001
5	6.6 ± 0.1	8.7 ± 0.8	(29 ± 4)	5.0 ± 0.2	0.11 ± 0.01
6	19 ± 4	6.8 ± 0.7	(24 ± 4)	(23 ± 4)	(24 ± 6)
7	8.7 ± 0.4	1.7 ± 0.1	(15 ± 3)	(21 ± 6)	0.48 ± 0.08
8	17 ± 2	13 ± 2	(14 ± 3)	(26 ± 6)	2.7 ± 0.8
9	14 ± 2	11 ± 1	(17 ± 1)	(22 ± 2)	(52 ± 3)
10	(62 ± 2)c	8.7 ± 0.5	(24 ± 3)	1.1 ± 0.3	(34 ± 3)
11	2.1 ± 0.2	7.3 ± 0.7	1.7 ± 0.3	3.1 ± 0.3	0.57 ± 0.02
12	1.9 ± 0.3	7.84 ± 0.03	8.2 ± 0.4	(50 ± 3)	0.24 ± 0.05
13	(57 ± 5)c	1.85 ± 0.04	(17 ± 1)	(25 ± 5)	(42 ± 1)
14	11 ± 2	8.1 ± 0.5	3.4 ± 0.2	(53 ± 3)	0.98 ± 0.14
quercetin	0.82 ± 0.07
donepezil		0.021 ± 0.002	2.3 ± 0.1
safinamide				(18 ± 3)	0.031 ± 0.001

^aData are the mean ± SEM of n = 3 experiments.

^bData in parentheses correspond to % of inhibition at 10 μM, or

^c100 μM for inhibition of Aβ₄₀ aggregation.